Ionis Pharmaceuticals (IONS) Research & Development (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Research & Development of $217.1 million for Q2 2026, little changed year-over-year from $217.5 million in Q2 2025, and up 3.3% quarter-over-quarter from $210.2 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Research & Development (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $217.1 million for Q2 2026.
- In Q2 2026, Research & Development changed 0.16% year-over-year to $217.1 million; the TTM figure through Jun 2026 stood at $924.7 million (up 4.66% YoY), while the FY2025 annual figure was $915.6 million, up 1.56% from the prior year.
- Research & Development for Q2 2026 stood at $217.1 million, up from $210.2 million in the prior quarter.
- The five-year high for Research & Development was $279.6 million in Q4 2025, with the low at -$444.9 million in Q4 2022.
- The 5-year median for Research & Development is $216.2 million (2023), against an average of $179.1 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development soared 157.67% in 2023, then fell 6.28% in 2025.
- Ionis Pharmaceuticals' Research & Development stood at -$444.9 million in 2022, then jumped by 157.67% to $256.6 million in 2023, then slipped by 4.31% to $245.5 million in 2024, then increased by 13.91% to $279.6 million in 2025, then dropped by 22.36% to $217.1 million in 2026.
- Business Quant data shows IONS's Research & Development at $217.1 million in Q2 2026, $210.2 million in Q1 2026, and $279.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 217.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 217.11 Mn |
| Mar 31, 2026 | 210.17 Mn |
| Dec 31, 2025 | 279.65 Mn |
| Sep 30, 2025 | 217.75 Mn |
| Jun 30, 2025 | 217.46 Mn |
| Mar 31, 2025 | 200.76 Mn |
| Dec 31, 2024 | 245.49 Mn |
| Sep 30, 2024 | 219.76 Mn |
| Jun 30, 2024 | 222.06 Mn |
| Mar 31, 2024 | 214.22 Mn |
| Dec 31, 2023 | 256.56 Mn |
| Sep 30, 2023 | 215.33 Mn |
| Jun 30, 2023 | 229.93 Mn |
| Mar 31, 2023 | 197.81 Mn |
| Dec 31, 2022 | -444.88 Mn |
| Sep 30, 2022 | 182.99 Mn |
| Jun 30, 2022 | 180.76 Mn |
| Mar 31, 2022 | 161.13 Mn |
| Dec 31, 2021 | -429.08 Mn |
| Sep 30, 2021 | 184.77 Mn |